Breast cancer drug could help more patients
The drug is Enhertu, an antibody-chemotherapy combo given by IV. It finds and blocks the HER2 protein on cancer cells, while also unloading a powerful cancer-killing chemical inside those cells. It belongs to a relatively new class of drugs called antibody-drug conjugates. The drug was already approved for HER2-positive breast cancer. In the new study, the drug lengthened the time patients lived without their cancer progressing and improved survival compared with patients given standard chemotherapy.

The study compared Enhertu to standard chemo in about 500 patients with HER2-low breast cancer that had spread or could not be treated with surgery. The drug stopped the progress of cancer for about 10 months compared with about 5 1/2 months in the group getting regular care. The drug improved survival by about six months (from 17.5 months to 23.9 months).

Researchers finally have a HER2-targeted drug that for the first time can target that low level of HER2 expression. This drug actually helps to define HER2-low breast cancer. It makes it, for the first time, a targetable population.

Source: https://medicalxpress.com/news/2022-06-breast-cancer-drug-patients.html
Like
Comment
Share